Company intelligence / Profile preview
ImmunoChem Therapeutics
Newton or Boston area, Massachusetts, United Statesict-rx.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Other
01
Overview
ImmunoChem Therapeutics is a clinical-stage biotech developing brain-specific, small molecule drugs to block neuroinflammation. Their lead candidate, MW189, is in an NIH-funded proof-of-concept Phase 2a trial for intracerebral hemorrhage. The company’s strategy is to first target orphan CNS diseases as a fast path to market and then expand into broader neurodegenerative indications such as Alzheimer’s disease. Clinical results are pending from ongoing trials.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Institutes of Health/National Institute of Neurological Disorders and Stroke/National Cancer Institute/National Institute on Aging via SBIR grantsAlzheimer's AssociationAlzheimer's Drug Discovery Foundation
Beyond the preview
Go deeper on ImmunoChem Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmunoChem Therapeutics.